Diese Seite ist nicht auf Deutsch verfügbar. Hier gelangen Sie zur deutschen Homepage.

This page isn’t available in English. Here, you’ll get to the English homepage.


Esta página no está disponible en español - Aquí podrá acceder a la página web en español.

Questa pagina non è disponibile in italiano. Qui si accede alla homepage in italiano.

Cette page n’est pas disponible en français. Ce lien vous conduira à la page d'accueil en français.

해당 페이지는 한국어가 지원되지 않습니다. 이 곳을 클릭하시면 한국어 버전 홈페이지로 이동하게 됩니다.

The Court of Justice of the European Union’s (CJEU’s) recently rendered Judgment in Santen v INPI (C-673/18) is expected to shape the landscape of patent extensions by Supplementary Protection Certificates (“SPCs”) more than any other decision of this court over the last 10 years and not to the favor of the researching pharmaceutical industry. It is generally considered a complete reversal of case law which the same court had initiated in 2012 (C-130/11; Neurim Pharmaceuticals (1991) Ltd v Comptroller). Click here to find our comments on CJEU Santen.

Should you have any questions or need more information, please do not hesitate to contact Dr. Klemens Stratmann or Dr. Bianca Vos.